CRBPCorbus Pharmaceuticals Hold...


$ 51.14 $ 2.26 (4.61 %)    

Friday, 05-Jul-2024 12:44:48 EDT
QQQ $ 495.15 $ 3.41 (0.69 %)
DIA $ 392.43 $ -0.21 (-0.05 %)
SPY $ 553.20 $ 1.41 (0.26 %)
TLT $ 92.50 $ 0.42 (0.46 %)
GLD $ 220.64 $ 1.13 (0.51 %)
$ 49.66
$ 48.88
$ 50.96 x 100
$ 0.00 x 0
$ 48.88 - $ 51.33
$ 3.03 - $ 55.41
133,160
na
412.7M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 b-riley-securities-initiates-coverage-on-corbus-pharmaceuticals-with-buy-rating-announces-price-target-of-85

B. Riley Securities analyst Kalpit Patel initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and an...

 corbus-pharmaceuticals-board-member-to-sell-shares-in-planned-trading

In a recent move signaling strategic financial planning, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that Dr...

 rbc-capital-maintains-outperform-on-corbus-pharmaceuticals-raises-price-target-to-82

RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price tar...

 oppenheimer-maintains-outperform-on-corbus-pharmaceuticals-raises-price-target-to-80

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target ...

 corbus-pharmaceuticals-announced-saturday-sys6002-crb-701-continues-to-demonstrate-safety-and-efficacy-in-nectin-4-positive-tumors-asco-2024-clinical-update-reveals

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for effica...